149 related articles for article (PubMed ID: 28132755)
1. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
[TBL] [Abstract][Full Text] [Related]
2. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
[TBL] [Abstract][Full Text] [Related]
3. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
4. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
5. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
[TBL] [Abstract][Full Text] [Related]
6. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.
de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
Verburg FA; Hänscheid H; Biko J; Hategan MC; Lassmann M; Kreissl MC; Reiners C; Luster M
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):896-903. PubMed ID: 20033685
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
9. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
10. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
[TBL] [Abstract][Full Text] [Related]
12. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
Taprogge J; Abreu C; Yusuf S; Ainsworth G; Phillip RH; Gear JI; Gregory R; Leek F; Murray I; Coulson AB; Brown SR; Du Y; Newbold K; Wadsley J; Flux GD
J Nucl Med; 2023 Jul; 64(7):1125-1130. PubMed ID: 37116914
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.
Saghari M; Gholamrezanezhad A; Mirpour S; Eftekhari M; Takavar A; Fard-Esfahani A; Fallahi B; Beiki D
Nucl Med Commun; 2006 Jul; 27(7):567-72. PubMed ID: 16794517
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract][Full Text] [Related]
15. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response.
Plyku D; Hobbs RF; Wu D; Garcia C; Sgouros G; Van Nostrand D
Ann Nucl Med; 2022 Mar; 36(3):213-223. PubMed ID: 35119623
[TBL] [Abstract][Full Text] [Related]
16. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
17. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry in differentiated thyroid carcinoma (12-1402R).
Minguez P; Genolla J; Celeiro JJ; Fombellida JC
Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I.
Jentzen W; Bockisch A; Ruhlmann M
J Nucl Med; 2015 Jun; 56(6):832-8. PubMed ID: 25858042
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
